L-T3 pharmaceutical equivalency, Part 2: New thyroid science

What does NEW thyroid science have to say on the topic of thyroid pharmaceutical equivalency? How many micrograms of L-T3 Liothyronine (i.e. Cytomel) are equivalent to L-T4 Levothyroxine (i.e. Synthroid)? Thyroid hormone pharmaceutical monographs currently provide very rigid and low-ratio equivalency statements: ERFA Canada says "Desiccated thyroid 60 mg is usually considered equivalent to ... …

Continue reading L-T3 pharmaceutical equivalency, Part 2: New thyroid science

No, 25 mcg of L-T3 Liothyronine isn’t equivalent to 100 mcg L-T4

In thyroid therapy, how many micrograms of Cytomel (T3) are equivalent to how many micrograms of Synthroid (T4)? Equivalency statements in the product monographs for Pfizer Canada's Cytomel and for ERFA Canada's "Thyroid" (NDT brand) claim that a 25 mcg dose of Liothyronine sodium (L-T3) is "considered equivalent" to 100 mcg / μg (0.1 mg) …

Continue reading No, 25 mcg of L-T3 Liothyronine isn’t equivalent to 100 mcg L-T4

2014 ATA Therapy guidelines: 4. Using Synthetic T3

This post continues my paraphrase of Jonklaas et al's 2014 "Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement." As I've explained in my previous post, I've decided not to let my summaries of ATA statements be an uninterrupted series of self-justifications and defenses. I've decided …

Continue reading 2014 ATA Therapy guidelines: 4. Using Synthetic T3

Dirty Money “Drug Short” episode and thyroid T3 Liothyronine

In the "Dirty Money" series on Netflix, the "Drug Short" episode (1) helped me understand some of the economic forces that may have influenced T3 / Liothyronine price hikes in the UK. It makes me concerned about the future of T3 pricing in Canada too. This episode focuses on Valeant, a Canadian pharmaceutical company that …

Continue reading Dirty Money “Drug Short” episode and thyroid T3 Liothyronine

Study the patients who need T3 and are harmed by its withdrawal

Clinical trials of T3 (Liothyronine) have been barking up the wrong tree. The limitations of their research designs are now actively harming patients who need T3 medication. Prices for T3 have been rising, medical prejudice against T3 is rising, worldwide T3 shortages are occurring, and patients who truly require T3 are being harmed by denying …

Continue reading Study the patients who need T3 and are harmed by its withdrawal

Trials of T3, desiccated thyroid and thyroxine in 1958

Here's my review of this treasure, an article about T3 therapy from the scientific literature in the 1950s... TITLE: "TRIIODOTHYRONINE—Clinical Effects in Patients with Suboptimal Response to Other Thyroid Preparations" -- LINK: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1512399/ In this article, "Thirty patients with evidence of hypometabolism or a clinically related condition were given triiodothyronine after suboptimal response to thyroxin or …

Continue reading Trials of T3, desiccated thyroid and thyroxine in 1958

HISTORY: L-T3 monotherapy in 1957

Sometimes science does not retain knowledge, but rather chooses to forget. After endocrinology fell in love with L-T4 monotherapy, it was too tempting to forget the history of the OTHER monotherapy -- L-T3 monotherapy. Modern doctors might assume that because they didn't have the TSH test back then, they were blind! They had no way …

Continue reading HISTORY: L-T3 monotherapy in 1957